Lumos Diagnostic Holdings (ASX:LDX) shares are surging, with as much as a 29.6% rise to A$0.092, marking their most significant intraday percentage increase since July 4.

The diagnostics solutions provider has inked an agreement with Henry Schein B.V., which forms part of U.S.-based health care products distributor Henry Schein Inc.

This agreement pertains to the FebriDx point-of-care (POC) test.

The partnership broadens the distribution of FebriDx, a rapid POC test designed to differentiate viral and bacterial acute respiratory infection, through Henry Schein’s medical business in the Netherlands.

The company’s stock reached its highest level since July 10.

Over 50 million shares were traded, compared to a 30-day average of approximately 27.9 million shares.

As of the most recent closing, the stock has gone up about 47.9% this year.

Lumos Diagnostic Holdings (ASX:LDX) is a provider of diagnostic solutions.